Bristol-Myers Tries To Block A Compulsory License In India

The latest tussle over compulsory licensing in India features Bristol-Myers Squibb and its Sprycel cancer treatment, although there is a tense subplot over legal machinations. The drugmaker maintains…
Read the full story: Pharmalot